News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
682,995 Results
Type
Article (38963)
Company Profile (276)
Press Release (643756)
Section
Business (203817)
Career Advice (1985)
Deals (35357)
Drug Delivery (84)
Drug Development (80769)
Employer Resources (168)
FDA (16084)
Job Trends (14796)
News (344458)
Policy (32431)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1212)
Approvals (16002)
Artificial intelligence (114)
Bankruptcy (352)
Best Places to Work (11458)
Biotechnology (196)
Breast cancer (101)
Cancer (886)
Cardiovascular disease (76)
Career advice (1656)
Cell therapy (193)
Clinical research (63889)
Collaboration (317)
Compensation (158)
COVID-19 (2520)
Cystic fibrosis (78)
Data (829)
Diabetes (128)
Diagnostics (6090)
Earnings (84091)
Employer resources (146)
Events (108757)
Executive appointments (239)
FDA (16514)
Funding (286)
Gene therapy (146)
GLP-1 (554)
Government (4316)
Healthcare (18649)
Infectious disease (2593)
Inflammatory bowel disease (101)
Interviews (308)
IPO (16264)
Job creations (3622)
Job search strategy (1415)
Layoffs (407)
Legal (7847)
Lung cancer (154)
Manufacturing (148)
Medical device (13140)
Medtech (13145)
Mergers & acquisitions (19100)
Metabolic disorders (348)
Neuroscience (1450)
NextGen Class of 2024 (6493)
Non-profit (4462)
Northern California (1177)
Obesity (209)
Opinion (175)
Patents (94)
People (56104)
Phase I (19814)
Phase II (28130)
Phase III (21009)
Pipeline (202)
Postmarket research (2553)
Preclinical (8422)
Radiopharmaceuticals (234)
Rare diseases (178)
Real estate (5888)
Regulatory (21427)
Research institute (2308)
Resumes & cover letters (349)
Southern California (1062)
Startups (3560)
United States (11422)
Vaccines (533)
Weight loss (156)
Date
Last 7 days (773)
Last 30 days (2634)
Last 365 days (35546)
2024 (30096)
2023 (40074)
2022 (51176)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35020)
2017 (32110)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (186)
Asia (36999)
Australia (6034)
California (2665)
Canada (1163)
China (207)
Colorado (115)
Connecticut (117)
Europe (79193)
Florida (385)
Georgia (98)
Illinois (306)
Indiana (175)
Kansas (95)
Maryland (507)
Massachusetts (2165)
Michigan (142)
Minnesota (246)
New Jersey (805)
New York (824)
North Carolina (656)
Northern California (1177)
Ohio (123)
Pennsylvania (737)
South America (1091)
Southern California (1062)
Texas (372)
Utah (77)
Washington State (315)
682,995 Results for "diamedica inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
DiaMedica Therapeutics Inc. today announced the closing of its previously announced $11.8 million private placement to accredited investors.
July 1, 2024
·
9 min read
BioMidwest
DiaMedica Therapeutics Announces $11.8 Million Private Placement
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors.
June 26, 2024
·
8 min read
BioMidwest
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia.
June 26, 2024
·
13 min read
Business
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024.
May 8, 2024
·
14 min read
Drug Development
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.
April 17, 2024
·
7 min read
Business
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th.
May 2, 2024
·
1 min read
Press Releases
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
October 9, 2024
·
8 min read
Business
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
March 19, 2024
·
17 min read
Business
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
DiaMedica Therapeutics Inc. announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer.
January 22, 2024
·
7 min read
Drug Development
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference being held in Phoenix, AZ from February 7 – 9, 2024.
January 29, 2024
·
2 min read
1 of 68,300
Next
